Clinical Microbiomics and CosmosID Inc. merge to push boundaries in microbiome research
Based in Denmark and Maryland, US, the CROs will offer global state-of-the-art multi-omics laboratories, advanced bioinformatics, applied AI and integrative systems biology expertise meeting GxP Standards.
Initially, the new company will be referred to as “CMC” until a new brand is launched in 2024. CMC will be headquartered in Copenhagen, Denmark and will employ more than 100 people in scientific, operational and commercial functions across three laboratory and bioinformatics sites in Europe and North America.
Clinical Microbiomics, particularly renowned for its pioneering work on clonal-level microbiome profiling, will bring the systems biology expertise and advanced, customised bioinformatics while CosmosID will offer CLIA-certified laboratory and interactive software for data delivery.
This is expected to make life easier for clients when running global microbiome studies.
Anders Grøn, CEO at Clinical Microbiomics, commented: “We are a company made up of scientists - Innovation is at the heart of our DNA. With this merger, we pool our expertise, resources, and commitment to pushing the boundaries of what’s possible in microbiome research.
"Our aim is clear: to enable and empower microbiome scientists with new tools, concepts and insights that will catalyse ground breaking discoveries. Microbiome is the next modality in healthcare, and we're here to help our clients and partners lead the way.”
Addressing key industry challenges
Standardisation of sampling, data generation and analysis in the field of microbiome research are major challenges in the world of microbiome research.
Dr. H. Bjørn Nielsen, chief scientific officer at Clinical Microbiomics, says the integration of the companies will provide a unique opportunity to accelerate standardisation to ensure reliability and comparability of results, addressing a major hurdle for global studies.
"The new entity allows access to local GxP laboratories with rapid turn-around times and adherence to regulatory standards. This is complemented by a cutting-edge analytical platform developed at the global center of expertise for advanced bioinformatics and integrative systems biology."
Manoj Dadlani, CEO at CosmosID, Inc., commented: “We are convinced this merger will make life easier for our clients. For the first time, it will be possible to ship samples to one location in each region for microbiome and metabolite profiling when running global microbiome studies – and to receive the data, results, and analytics in a standardized form through interactive software and/or a customized report. We're excited about the convenience and excellence this brings to our clients and the broader scientific community.”
It is only 12 months since the merger between Clinical Microbiomics and MS-Omics, a leading metabolomics company, and the company’s trajectory of rapid expansion continues with the CosmosID merger.
Dr Nielsen added: “The merger allows us to invest more resources to improve our offerings and stay at the forefront of microbiome science. We plan to make advancements in lab technology and computational methods, all guided by our client needs and our commitment to high standards.”
New executive management following the merger will be: Anders Grøn, CEO; Manoj Dadlani, CCO & President, North America; Henrik Knudsen, CFO; H. Bjørn Nielsen, CSO; Kelly Moffat, US-operations & Global NGS Technologies; Morten Danielsen, EU Morten Danielsen, EU operations & Global Metabolomics Technologies.
